Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	UL24	Synonyms	None	Type of gene	protein coding
Chromosome	None	Map location	NC_001806.2 (47738..52772)	dbXrefs
Description	nuclear protein UL24

Gene symbol	UL55	Synonyms	None	Type of gene	protein coding
Chromosome	None	Map location	NC_001806.2 (115497..116104)	dbXrefs
Description	nuclear protein UL55

Gene symbol	UL56	Synonyms	None	Type of gene	protein coding
Chromosome	None	Map location	NC_001806.2 (116197..116926, complement)	dbXrefs
Description	membrane protein UL56

Gene symbol

tk

GTO ID	GTC0004
Trial ID	NCT00012155
Disease	Colorectal Cancer \| Metastatic Cancer
Altered gene	UL24\|UL55\|UL56\|tk
Therapeutic/Target gene	Therapeutic gene
Therapy	DNA oncolytic virus
Treatment	NV1020
Phase	Phase1
Recruitment status	Completed
Title	A Phase I, Open-Label, Dose-Escalating Study Of The Safety, Tolerability, And Anti-Tumor Activity Of A Single Intrahepatic Arterial Injection Of Genetically Engineered Herpes Simplex Virus, NV1020, In Subjects With Adenocarcinoma Of The Colon With Metastasis To The Liver
Year	2001
Country	United States
Company sponsor	Memorial Sloan Kettering Cancer Center
Other ID(s)	MSKCC-00022\|CDR0000068488\|MGENE-NR1-001\|NCI-G01-1920

Vector information

Vector	herpes simplex virus
Viral genome modification	NV1020, has a 15-kb deletion over the joint region of the HSV-1 genome. This deletion encompasses the region of the genome encoding ICP0, ICP4, latency-associated transcripts (LATs) , and one copy of the neurovirulence gene (134. 5), a fragment of HSV-2 DNA from the HindIII l region encoding several glycoproteins was inserted into the deleted joint region. It also has a 700-bp deletion of the endogenous TK locus that prevents expression of the overlapping transcripts belonging to the UL24 gene.

Clinical Result

Cohort 1

Administration route	intrahepatic arterial injection
Dosage	3E6~1E8 plaque-forming units
Pts	12
Age	Adult, Older_Adult
Outcome	In the first week after viral administration only rare and minor increases were noted for tumor necrosis factor-alpha (six samples; three patients; peak, 40 pg/ml), interleukin (IL)-1 (two samples; two patients; peak, 28 pg/ml), and interferon-y (four samples; two subjects; peak, 54 pg/ml). No IL-2 was detected.
Adverse reactions	1/12(transient rise in serum y-glutamyltransferase); 1/12(one diarrhea); 1/12(leukocytosis)
References	PMID: 17107303

Relationship Graph

Overview of Knowledge Graph